Steve Scala
Stock Analyst at TD Cowen
(2.76)
# 1,925
Out of 4,711 analysts
31
Total ratings
69.23%
Success rate
12.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $175.58 | +28.15% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $57.33 | +2.91% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $65.35 | +45.37% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $98.05 | +37.68% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $26.36 | +21.40% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $430 → $500 | $767.76 | -34.88% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $97.11 | +8.12% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $24.92 | +120.71% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $175.58
Upside: +28.15%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $57.33
Upside: +2.91%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $65.35
Upside: +45.37%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $98.05
Upside: +37.68%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $26.36
Upside: +21.40%
Eli Lilly
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $767.76
Upside: -34.88%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $97.11
Upside: +8.12%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $24.92
Upside: +120.71%